vTv Therapeutics (NASDAQ:VTVT) Rating Increased to Strong-Buy at Lifesci Capital

vTv Therapeutics (NASDAQ:VTVT) was upgraded by equities research analysts at Lifesci Capital to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports.

A number of other brokerages have also issued reports on VTVT. Weiss Ratings lowered vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Rodman & Renshaw assumed coverage on shares of vTv Therapeutics in a report on Tuesday, June 30th. They issued a “buy” rating and a $67.00 price target on the stock. BTIG Research boosted their price target on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Zacks Research lowered vTv Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Finally, HC Wainwright reduced their price objective on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, vTv Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Stock Up 0.2%

Shares of NASDAQ VTVT opened at $33.47 on Wednesday. The company has a market cap of $131.87 million, a PE ratio of -31.58 and a beta of 0.29. The firm’s 50-day moving average price is $33.05 and its 200-day moving average price is $34.57. vTv Therapeutics has a 52-week low of $18.00 and a 52-week high of $44.00.

vTv Therapeutics (NASDAQ:VTVT) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). As a group, equities research analysts anticipate that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On vTv Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. bought a new position in vTv Therapeutics in the 4th quarter worth about $221,000. Geode Capital Management LLC grew its stake in vTv Therapeutics by 84.3% in the fourth quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares in the last quarter. Finally, 683 Capital Management LLC bought a new position in vTv Therapeutics in the fourth quarter worth approximately $731,000. Institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.